For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Attruby represents a significant change. These novel therapies preserve the transthyretin protein, preventing its harmful build-up and reducing the burden of the condition . Patients are now seeing positive outcomes in thei